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Abstract 
Psoriasis is a common inflammatory skin disease and dendritic cells (DCs) play crucial role in 
the development of skin inflammation. Although the characteristics of skin DCs in psoriasis 
are well defined, less is known about their peripheral blood precursors. Our aim was to 
characterize the phenotypic features as well as the cytokine and chemokine production of 
CD1c
+
 myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) in the blood samples of psoriatic 
patients. Blood DCs were isolated by using a magnetic separation kit, and their 
intracytoplasmic cytokine production and CD83/CD86 maturation/activation marker 
expression were investigated by 8-colour flow cytometry. In CD1c
+
 mDCs the intracellular 
productions of Th1, Th2, Th17, Th22 and Treg polarizing cytokines were examined 
simultaneously, whereas in pDCs the amounts of IFNα as well as IL-12, IL-23 and IL-6 were 
investigated. The chemokine production of both DC populations was investigated by flow-
cytometry and ELISA. According to our results psoriatic CD1c
+ 
mDCs were in a premature 
state since their CD83/CD86 maturation/activation marker expression, IL-12 cytokine, 
CXCL9 and CCL20 chemokine production was significantly higher compared to control cells. 
On the other hand, blood pDCs neither produced any of the investigated cytokines and 
chemokines nor expressed CD83/CD86 maturation/activation markers. Our results indicate 
that in psoriasis not only skin but also blood mDCs perform Th1 polarizing and Th1/Th17 
recruiting capacity, while pDCs function only in the skin milieu.  
 
 
Keywords: psoriasis, dendritic cell, cell surface marker, T cell polarizing cytokine, 
chemokine 
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Abbreviations: mDCs/pDCs/DDCs, myeloid/ plasmacytoid/ dermal dendritic cells; IL, 
interleukin; IFNα, interferon alpha; TNFα, tumor  necrosis factor alpha;  iNOS, inducible 
nitric oxide synthase; PASI, Psoriasis Area and Severity index; PBMCs, peripheral blood 
mononuclear cells; FSC/SSC forward  and side light scattering ; RT,  room temperature;  
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1. Introduction 
 
Psoriasis is a common chronic inflammatory skin disease affecting approximately 2% 
of the population worldwide [1-3]. Both activated dendritic cells (DCs) and T cells play a 
crucial role in the pathogenesis of this disease, since their abnormal activation and a 
Th1/Th17 cytokine environment lead to the typical exaggerated proliferation of keratinocytes, 
which is characteristic to psoriasis [4].  
Skin DCs contribute both to the initiation and to the maintenance of the disease [4]. 
Plasmacytoid DCs (pDCs), which are currently considered to promote inflammation after 
being activated by LL-37/self-DNA complexes, are the main sources of IFNα [5], which 
induce the IFNα dependent maturation of myeloid DCs (mDCs) [6]. A 30-fold increase in the 
number of CD11c
+
 mDCs was detected in the dermal compartment of psoriatic skin lesions 
compared to uninvolved or normal skin [7], and these cells are responsible for further 
sustenance and amplification of the T cell mediated inflammatory processes [8-10]. In 
psoriasis the mDCs can be divided into two distinct populations: CD11c
+
 CD1c
-
 inflammatory 
DCs, also known as TIP-DCs and the CD11c
+
 CD1c
+
 resident DCs, also known as dermal 
DCs (DDCs) [11]. TIP-DCs, beyond their TNFα and iNOS production [7,12-14], together 
with the so called “background” CD1c+ DDCs, are important sources of Th17 activating 
cytokine IL-23 [10,11].  Moreover CD1c
+
 DDCs are potential producers of the Th1 polarizing 
cytokine IL-12 [7,14,15]. 
In addition to their T cell polarizing cytokine production DCs are important sources of 
chemokines. Psoriatic skin exhibits increased expression of several chemokines [16-18], and 
skin DCs were found to produce CXCL1, CXCL8, CXCL9, CXCL10 as well as CCL20 
chemokines [15].  CXCL1, CXCL9 and CXCL10 are chemoattractants for Th1 lymphocytes, 
CXCL8 recruits neutrophils, while CCL20 attracts Th17 lymphocytes, DCs and monocytes 
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[19]. The precise contribution of skin DC subsets to the chemokine secretion is not clearly 
defined, but they are considered to be released by Langerhans cells, DDCs, TIP-DCs and also 
by pDCs [15,16,19,20].  
Taken together, skin DCs are important in the development of psoriatic skin 
inflammation. At the same time their blood precursors and their phenotypic and functional 
characteristics in psoriasis are scarcely explored.  Since it has emerged that peripheral blood 
pre-DCs can serve as precursors of not just DDCs, but also of TIP-DCs [21,22] [17,23] , the 
relevance of their characterization is essential. 
We aimed to examine the characteristic features of psoriatic blood CD1c
+
 mDCs and 
pDCs focusing on their activation and maturation stages, as well as on their cytokine and 
chemokine release. Our results indicate that not only skin but also peripheral blood mDCs 
derived from psoriatic patients are able to produce disease-specific Th1/ Th17 cytokines and 
chemokines, while pDCs seem to function only in the skin milieu.  
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2. Materials and methods  
 
2.1. Patients and controls 
Peripheral blood was obtained from patients with psoriasis (n=21, 13 males, 8 females, 
mean age: 51.5±13.8 years,) and from healthy controls (n=17) matching in gender and age. 
Randomly selected patients took part in the CD1c
+ 
mDC and pDC investigations or in ELISA 
measurements, since the number of the extractable cells from one patient limited the number 
of experiments/patients. 12 patients /9 controls were recruited to the cytokine examination of 
CD1c
+ 
mDCs, 5 patients/ 4 controls to the pDCs’ investigations together with the chemokine 
investigations of CD1c
+ 
mDCs, while 4 patients/4 controls were involved in the ELISA 
experiments.  All patients who took part in this study had moderate-to-severe psoriasis, based 
on Psoriasis Area and Severity index (PASI ) calculation (mean PASI: 23.9±10.1) and had 
received neither systemic treatment nor phototherapy for their psoriasis at least 4 weeks prior 
to blood sampling. Informed consent was obtained from all participants according to the 
Declaration of Helsinki principles. The local Ethics Committee of the University of Debrecen, 
Hungary, approved the study. 
 
2.2. Cell isolation and culture  
Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll-Paque Plus (GE 
Healthcare Bio-Science AB, Uppsala, Sweden) gradient centrifugation from the peripheral 
blood of both psoriatic patients and healthy controls. Blood DCs containing both CD1c
+ 
myeloid DCs and pDCs were isolated from PBMCs using the Blood Dendritic Cell Isolation 
Kit (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) according to the instructions of 
the manufacturer. For ELISA examinations CD1c
+
 DCs were separated using a CD1c
+
 Blood 
DC isolation kit (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany). Purified blood  
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DCs were cultured in RPMI 1640 (Miltenyi Biotech GmbH) medium supplemented with 
antibiotics (PAA Laboratories GmbH, Pasching, Austria) and 10% FBS (Lonza Group Ltd, 
Basel, Switzerland) for 6 hours. For chemokine ELISA experiments supernatants of purified 
CD1c
+
 mDCs were collected after 24h culturing. 1x 10
5
 dendritic cells were cultured in 200 μl 
cell culture medium in a well of a 96 well-plate with flat bottom. Since our aim was to detect 
the characteristics of DCs in physiological conditions, moreover we could detect prominent 
cytokine and chemokine production even without stimulation, no further stimulations were 
applied during the examinations. 
 
2.3. Cell surface marker and intracytoplasmic cytokine staining  
 
Cytokine/chemokine production of the cells was analysed after 6 hours of incubation 
with 3μg/ml Brefeldin A (eBioscience Inc, San Diego, CA, USA) solution for the inhibition 
of their secretion. After incubation, the cells were harvested, washed in phosphate-buffered 
saline (PBS) with 5% FBS and 0.5mM EDTA, and then resuspended in FACS buffer (PBS 
containing 1% bovine serum albumin) and aliquoted  into tubes (one for the negative control, 
four for the staining). Cells were first stained with the following fluorescent dye-conjugated 
monoclonal antibodies against the following cell surface markers: anti-CD1c-APC-Cy7 and 
anti-CD11c-APC or anti-CD11c-FITC to identify CD1c
+
/CD11c
+
 mDCs, anti-CD303-PerCP-
Cy5.5 and anti-CD304-Pacific Blue to identify pDCs, and anti-CD86-PE or anti-CD83-
PerCP-Cy5.5 to examine the maturation or activation state. Cells were stained for 30 minutes 
in the dark at 4
o
C. Stained cells were washed with FACS buffer and fixed by Intracellular (IC) 
fixation buffer (eBioscience, San Diego, CA, USA) for 20 minutes in the dark at room 
temperature (RT). Then cells were washed with 1x Permeabilization Buffer (eBioscience) and 
after centrifugation, the pellet was resuspended in 100µl 1x Permeabilization Buffer and 
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stained with assorted combinations of the following intracellular cytokine/chemokine specific 
antibodies: PE labelled human monoclonal antibodies against TGFβ, IL-23p19, IFN-α, 
CCL17, CXCL1, CXCL10; FITC labelled antibodies against IL-6, IL-12, IL-2, CXCL8; 
PerCP-Cy5.5 labelled IL-10, IL-4, TNFα and APC labelled anti-human CXCL9 and CCL20.  
All the antibodies are from Biolegend, San Diego, CA, USA, except for TGFβ, CCL17, 
CXCL1, CCL20 which are from R&D Systems, Minneapolis, MN, USA. Then the cells were 
incubated in the dark at RT for 20 minutes and washed first with 1x Permeabilization Buffer 
and subsequently with FACS Buffer.  After centrifugation, the pellet was resuspended in 200 
µl FACS buffer and kept in 4oC until measurement. Unstained cells served as negative 
control. 
 
2.4. Flow cytometry 
Flow cytometric measurements were carried out on fixed cells on a Beckman Coulter Navios 
cytometer (Beckman Coulter) applying eight colour flow cytometric protocol.  Typically 
100,000–500,000 cells were acquired, depending on the yield of cell isolation. Forward (FSC) 
and side light scattering (SSC) were used to detect cellular objects and to exclude debris and 
clustered cells.  Dendritic cell subtypes were gated on the basis of the following backbone 
markers’ expression: CD11c, CD1c, CD304, CD303.  Expression of cytokines/chemokines 
and activation markers were investigated in the gated pDC or CD1c
+ 
mDC populations. List 
mode data (LMD) files were analyzed using Navios software v. 1.1 and Kaluza
TM
 software 
version 1.2 (Beckman Coulter). Histograms were plotted on 'logicle' axes in Kaluza software. 
 
2.5. Identification of the secreted chemokines by ELISA 
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The exact amount of the psoriasis related CXCL8, CXCL9, CXCL10 and CCL20 chemokines 
was also analysed using CXCL8/IL8, CXCL9/MIG, CXCL10/IP10 and CCL20/MIP-3α 
Quantikine ELISA Kits (R&D Systems), all according to the manufacturer’s instructions. The 
supernatants of CD1c
+
 mDCS originated from 4 patients and 4 controls were investigated. 
The detection limits in Quantikine ELISAs are: CXCL1- 10 pg/ml, CXCL8- 3.5 pg/ml, 
CXCL9- 3.84pg/ml, CXCL10- 1.67 pg/ml. CCL20- 0.47pg/ml. 
 
2.6. Statistical analysis 
To assess the distribution of the data, the Kolmogorov–Smirnov test was used. 
Because of their normal distribution, we determined mean ± standard error of mean (SEM) 
values. We used the independent t-test for statistical comparison of two or more experimental 
data, respectively. Differences were considered to be significant when p<0.05. (*p<0.05; 
**p<0.01; ***p<0.001). Analysis of correlations was performed by Spearman r test. SPSS 
ver. 18.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis.  
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3. Results 
 
3.1. Psoriatic blood CD1c
+ 
mDCs exhibit premature state and produce IL-12  
From the peripheral blood of patients with psoriasis and healthy volunteers CD1c
+
 
mDCs and pDCs were separated parallel by using Blood DC isolation kit.  To examine the 
phenotypic features and the cytokine/chemokine production of the CD1c
+
 mDCs, 
CD1c
+
/CD11c
+
 DCs were gated from this DC “cocktail”.  
The CD83 maturation marker appeared significantly more frequently on the surface of 
psoriatic blood CD1c
+
 mDCs compared to control cells (74.9 % vs. 30.42 %, respectively, 
p=0.0103 Figure 1.A). Most of the cells in both groups expressed CD86 activation marker, 
but significantly increased fluorescence intensity could be detected in the psoriatic group 
(CD86 MFI 3.68 vs. 3.28 respectively, p=0.0445 Figure 1.B).  
In psoriatic blood CD1c
+ 
mDCs Th1 (IL-12), Th2 (IL-2, CCL17), Th17 (TGFβ, IL-23, 
IL-6), Th22 (IL-6 and TNFα), and Treg (TGFβ and IL-10) polarizing cytokines were 
simultaneously detected by flow-cytometry using an 8-color staining method. Significantly 
higher percentage of psoriatic CD1c
+
 mDCs produced IL-12 compared to control cells 
(68.9%.  vs. 12.8%, respectively, p=0.013 Figure 2.A.). Not only the number of IL-12 positive 
cells, but also the amount of IL-12 in these cells was significantly higher (IL-12 MFI: 1.01 vs. 
0.75 in psoriatic CD1c
+ 
mDCs vs. control cells, p=0.008, Figure 2. B.). Furthermore the mean 
fluorescence intensity of IL-12 correlated significantly with the clinical severity index of 
patients (PASI) (Spearman test, r=0,6110; p=0.0494; Figure 2.C), and the number of IL-12 
producing cells and PASI also showed some, but not significant correlation (data not shown). 
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3.2. Psoriatic blood pDCs are inactive and exhibit an immature phenotype 
 To investigate the maturation/activation status and the cytokine production of blood 
pDCs, CD11c
-
/CD1c
-
/ CD303
+
 (BDCA2
+
) /CD304
+
 (BDCA4
+
) cells were gated from the 
“DC cocktail” obtained after using Blood DC isolation kit.  
Blood pDCs exhibited an inactive phenotype, since they could not express either 
CD83 maturation or CD86 activation markers reflecting the maturation/activation status of the 
cells. When examining the function of these cells we focused on the detection of IL-12, IL-23 
and IL-6, as psoriasis-related cytokines and also on IFNα, the main cytokine produced by 
pDCs in psoriatic skin. None of these cytokines could be detected in psoriatic blood pDCs.  
 
3.3. Psoriatic blood CD1c
+ 
mDCs, but not pDCs produce Th1/Th17 recruiting chemokines 
3.3.1. Investigation of intracytoplasmic chemokine production by flow-cytometry 
The chemokine production potential of both psoriatic blood CD1c
+ 
mDCs and pDCs 
was examined first by flow-cytometry. Chemokines, published earlier to be produced by 
psoriatic skin DCs [15], were investigated: CXCL1, CXCL8, CXCL9 and CXCL10 as Th1, 
and CCL20 as Th17 recruiting chemokines. 
Although the frequency of chemokine producing DCs were nearly similar in patients 
and controls (Figure 3. A.), our investigations revealed that psoriatic blood CD1c
+ 
mDCs were 
able to produce CXCL9 and CCL20 in a significantly higher (CXCL9 MFIs: 3.83 vs. 1.72, 
p<0.0001, CCL20 MFIs: 3.14 vs. 1.36, p=0.0275 in patient and control groups respectively, 
Figure 3. B.), whereas CXCL8 and CXCL10 in a slightly higher amount (CXCL8 MFIs: 2.85 
vs. 2.56; CXCL10 MFIs: 0.85 vs. 0.78; neither are significant, Figure 3.B.) compared to 
healthy control cells.  The CXCL1 chemokine production was almost equal in the two mDC 
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groups (CXCL1 MFIs: 1.05 vs. 1.01, not significant). The chemokine production of psoriatic 
blood pDCs was negligible compared to CD1c
+ 
mDCs (Figure 3.B.) and was similar to 
control cells.  
 
3.3.2. Measurement of released chemokines by ELISA 
Since mDCs were found to produce different Th1/Th17 recruiting chemokines, their 
release was also investigated by ELISA from the supernatant of CD1c
+
 mDCs.  
Psoriatic blood CD1c
+
 mDCs were able to release CCL20 in a significantly higher and 
CXCL8, CXCL10 in a markedly higher amount compared to control CD1c
+ 
mDCs (CCL20 
mean concentration: 47.2 pg/ml vs. 4.9 pg/ml, p=0.0042, CXCL8 mean concentration: 29.9 
ng/ml vs.14.01ng/ml, not significant; CXCL10 mean concentration: 92.07 pg/ml vs. 25.2 
pg/ml, not significant, Figure 4).  Interestingly CXCL9 could not be detected at a notable 
level in the supernatant of either psoriatic or control CD1c
+ 
mDCs, in contrast to the results of 
the flow-cytometry investigations (data not shown). 
 
4. Discussion 
 
The contribution of distinct skin DC subsets to the pathogenesis of psoriasis was well 
explored in the last decade [14], while the role of blood DCs is less understood.   Since CD1c
+
 
blood mDCs and pDCs are potential precursors of skin DCs, in this study we focused on the 
examination of the phenotypic characteristics and cytokine/chemokine production of these 
poorly investigated cells in psoriatic patients [21,22]. Investigating blood precursor DCs can 
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give information on whether DCs in psoriasis acquire their specific characteristics exclusively 
in the skin microenvironment or if they are already influenced even in the blood by some 
disease-specific factors. These questions can be answered by examining DCs directly 
separated from peripheral blood, instead of applying DCs that have been differentiated in 
vitro from monocytes, and although this method results in fewer cells from the same amount 
of blood, their investigation can give more information on the physiological condition. 
  In our experiment we simultaneously investigated the expression of 
CD83/CD86 maturation and activation markers and the production of Th1, Th2, Th17, Th22 
and Treg polarizing cytokines in circulating CD1c
+ 
mDCs. Although blood DCs generally 
circulate in an inactive form, according to our results psoriatic blood CD1c
+ 
mDCs are in a 
pre-mature state, since they expressed CD83 and CD86 markers in a significantly higher 
amount. Furthermore they produced significantly more Th1 polarizing cytokine IL-12, which 
correlated with the severity of the disease. In psoriasis IL-12, which is considered to be one of 
the key cytokines, is produced by skin mDCs [7,10,11,14], but our results indicate that their 
peripheral blood precursors are also potential sources of this cytokine.  Although it is well 
known that psoriatic skin DCs express CD83 and CD86 DC maturation/activation markers 
[24] and release IL-12 and IL-23 cytokines [7,10,11,14,15], data regarding the phenotype and 
cytokine production  of their peripheral blood precursors are hardly available [25], our results 
may fill the niche.   
The pre-activated status of psoriatic CD1c
+ 
mDCs was confirmed not only by their 
cytokine production but also by their chemokine secretion, since both CXCL9 and CCL20 
were produced in a significantly, while CXCL8 and CXCL10 in a markedly higher amounts 
compared to control cells. These results suggest that blood CD1c
+
 mDCs in psoriatic patients 
have an increased potential to produce Th1/Th17 recruiting chemokines. Our results are 
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consistent with the observations of Fujita et al., [15], since they detected a similar Th1/Th17 
recruiting chemokine production in psoriatic skin DCs. 
In contrast to our observations on CD1c
+
 mDCs, investigations on the activation/ 
maturation status and on the cytokine/chemokine production of blood pDCs revealed that 
neither psoriasis related cytokines nor a significant amount of chemokines could be 
produced by these cells. They also exhibited an inactive phenotype, since the expression of 
CD83 maturation and CD86 activation markers could not be detected on their surface. The 
hypothesis suggested by Nestle et al. could be strengthened by our results, that despite the 
crucial role of skin pDCs in the initiation of psoriasis,  their peripheral blood precursors 
circulate in resting state and became activated locally in the psoriatic skin milieu [5].  
Taken together, the characterization of cell surface markers and cytokine/chemokine 
production of blood precursor DCs in psoriatic patients indicate that while pDCs exhibit a 
resting phenotype, CD1c
+
 mDCs are in a pre-mature stage, and are able to produce disease-
specific mediators even in the peripheral blood. The lack of maturation/activation markers and 
the functional inactivity of pDCs suggest that their activation is performed only in the skin 
milieu. In contrast, the pre-mature status of psoriatic CD1c
+ 
mDCs proven by their phenotypic 
and functional properties suggests that their maturation is markedly influenced by the 
microenvironment even in the blood and not only in the skin milieu, although this 
proinflammatory blood milieu is probably the consequence of the primarily occurring skin 
inflammation. The bloodstream of psoriatic patients suffering from severe skin lesions 
contains a unique set of cytokines, such as TNF-α, IFNγ, IL-6, IL-8, IL-12 and IL-18 [26]. 
Among them TNF-α and IL-6, together with IFN-α may allow blood pre-mDCs to reach this 
pre-mature state [3], and these pre-activated cells can be further activated easily and rapidly 
after entering the skin leading to a vicious circle.  Novel biological agents (e.g. anti-TNF-α 
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therapy) can have a doubly beneficial impact by modifying the effect of these cytokines both 
in the skin and in the blood of the patients, thus influencing the maturation and the function of 
the pre-DCs in the blood.  
 
5. Conclusion 
 
In this study we have examined the characteristic features of psoriatic blood CD1c
+
 
mDCs and pDCs focusing on their activation and maturation stages, as well as on their 
cytokine and chemokine release. Our results indicate that not only skin but also peripheral 
blood CD1c
+
 mDCs derived from psoriatic patients are able to produce disease-specific Th1/ 
Th17 cytokines and chemokines, while pDCs seem to function only in the skin milieu.  
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Figure 1. Phenotypic characterization of blood mDCs in psoriasis. A. The CD83 
maturation marker appeared significantly more frequently on the surface of psoriatic blood 
mDCs compared to control cells. B. Significantly increased CD86 fluorescence intensity 
could be detected in the psoriatic group. Columns represent the mean ± SEM of 12 patients 
and 9 controls. * p<0. 05, ** p<0.01  
 
Figure 2. Cytokine production of blood mDCs in psoriasis. A. The percentage of IL-12 
producing mDCs was significantly higher in psoriasis compared to controls. Percentages of 
cytokine producing cells are described using mean ± SEM;  B. Not only the number of IL-12 
positive cells, but also the amount of IL-12 produced by these cells was significantly higher 
(IL-12 MFI: 1.01 vs. 0.75 in psoriatic mDCs vs. control cells, p=0.008). C. The mean 
fluorescence intensity of IL-12 in mDCs significantly correlated with PASI. (Spearman test, 
r=0.6110; p=0.0494).  
patients n=12; controls n=9; **p<0.01; *** p<0.001 
 
Figure 3. Chemokine production of blood mDCs and pDCs investigated by flow-
cytometry. A. The frequency of chemokine producing DCs were nearly similar in patients 
and controls. B. Blood CD1c
+
 mDCs produced CXCL9 and CCL20 in a significantly higher 
amount. The chemokine production of pDCs was negligible compared to mDCs. Columns 
represent the mean ± SEM of five patients and four controls.  
* p<0.05, *** p<0.001 
Figure 4. Chemokine production of blood CD1c+ mDCs investigated by ELISA. 
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  Psoriatic CD1c
+
 mDCs produced CCL20 in a significantly and CXCL8 and CXCL10 in a 
markedly higher amount than control DCs. Columns represent the mean ± SEM of four 
patients and four controls.  ** p<0.01 
